{"id":25629,"date":"2014-06-12T12:18:11","date_gmt":"2014-06-12T16:18:11","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=25629"},"modified":"2014-06-12T12:18:11","modified_gmt":"2014-06-12T16:18:11","slug":"geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629","title":{"rendered":"Geron Corporation (NASDAQ:GERN) Surging on the FDA Lifting a Partial Hold Ban on Cancer Trial"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 06\/12\/2014 (wallstreetpr) \u2013\u00a0<b>Geron Corporation (NASDAQ:GERN)&#8217;s<\/b> shares are surging in the market by 29.18% after U.S regulators lifted a\u00a0 partial hold on the company\u2019s drug that is intended to treat a\u00a0 rare form of Leukemia. The company is currently developing its imetelstat drug for a form of Leukemia commonly known as Myelofibrosis. The partial hold had been issued on March 2014, as a result, of safety signals being detected on clinical trial.<\/p>\n<p style=\"text-align: justify;\"><b>Reasons behind the Partial Hold<\/b><\/p>\n<p style=\"text-align: justify;\">The U.S Food and Drug Administration withdrew the partial hold after Mayo Clinic; the drugs trial sponsor shed more light on the reversibility of the drugs toxic that was found to take place in the liver. Myelofibrosis is a form of bone marrow cancer that normally leads to a severe form of anemia causing fatigue as well as enlarged spleen and the liver.<\/p>\n<p style=\"text-align: justify;\">The FDA had issued a partial hold on the drugs trials after a number of patients under its medications showed low-grade liver function abnormalities. The company was only allowed to use the drug on patients who showed significant improvement under it. The Company\u2019s trials on two other diseases thrombocythemia and myeloma still remain under hold. Geron is thus unable to submit any clinical trial protocols in the U.S.<\/p>\n<p style=\"text-align: justify;\"><b>Dr. Ayalew Requested to Carry out Follow Up<\/b><\/p>\n<p style=\"text-align: justify;\">Dr. Ayalew Tefferi of Mayo Clinic was requested to carry out a follow up on the reversibility of hepatotoxicity for all patients who had received imetelstat in Myelofibrosis IST. On a letter to the FDA, Dr. Ayalew concluded that it would be okay for Myelofibrosis IST to proceed. Myelofibrosis IST ceased to enroll new patients as of January 2014 with Mayo Clinic consequently not citing any safety concerns behind the decision.<\/p>\n<p style=\"text-align: justify;\">The lifting of the ban comes as the company\u2019s stock continues to be rated as a \u201csell\u201d by TheStreet research firm. The rating was prompted by the fact that the company\u2019s revenue fell by 38% but did not hurt the company\u2019s bottom line, as earnings per share increased.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 06\/12\/2014 (wallstreetpr) \u2013\u00a0Geron Corporation (NASDAQ:GERN)&#8217;s shares are surging in the market by 29.18% after U.S regulators lifted a\u00a0 partial hold on the company\u2019s [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":17274,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2715,2716],"stock_ticker":[],"class_list":["post-25629","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-geron-corporation-nasdaqgern","tag-nasdaqgern","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Geron Corporation (NASDAQ:GERN) Surging on the FDA Lifting a Partial Hold Ban on Cancer Trial - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Geron Corporation (NASDAQ:GERN) Surging on the FDA Lifting a Partial Hold Ban on Cancer Trial - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 06\/12\/2014 (wallstreetpr) \u2013\u00a0Geron Corporation (NASDAQ:GERN)&#8217;s shares are surging in the market by 29.18% after U.S regulators lifted a\u00a0 partial hold on the company\u2019s [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-06-12T16:18:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Geron-Corporation-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Alan Masterson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alan Masterson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629\"},\"author\":{\"name\":\"Alan Masterson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\"},\"headline\":\"Geron Corporation (NASDAQ:GERN) Surging on the FDA Lifting a Partial Hold Ban on Cancer Trial\",\"datePublished\":\"2014-06-12T16:18:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629\"},\"wordCount\":357,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Geron-Corporation-logo.jpg\",\"keywords\":[\"Geron Corporation (NASDAQ:GERN)\",\"NASDAQ:GERN\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629\",\"name\":\"Geron Corporation (NASDAQ:GERN) Surging on the FDA Lifting a Partial Hold Ban on Cancer Trial - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Geron-Corporation-logo.jpg\",\"datePublished\":\"2014-06-12T16:18:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Geron-Corporation-logo.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Geron-Corporation-logo.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Geron Corporation (NASDAQ:GERN) Surging on the FDA Lifting a Partial Hold Ban on Cancer Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\",\"name\":\"Alan Masterson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"caption\":\"Alan Masterson\"},\"description\":\"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Geron Corporation (NASDAQ:GERN) Surging on the FDA Lifting a Partial Hold Ban on Cancer Trial - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629","og_locale":"en_US","og_type":"article","og_title":"Geron Corporation (NASDAQ:GERN) Surging on the FDA Lifting a Partial Hold Ban on Cancer Trial - Wall Street PR","og_description":"Boston, MA 06\/12\/2014 (wallstreetpr) \u2013\u00a0Geron Corporation (NASDAQ:GERN)&#8217;s shares are surging in the market by 29.18% after U.S regulators lifted a\u00a0 partial hold on the company\u2019s [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-06-12T16:18:11+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Geron-Corporation-logo.jpg","type":"image\/jpeg"}],"author":"Alan Masterson","twitter_misc":{"Written by":"Alan Masterson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629"},"author":{"name":"Alan Masterson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90"},"headline":"Geron Corporation (NASDAQ:GERN) Surging on the FDA Lifting a Partial Hold Ban on Cancer Trial","datePublished":"2014-06-12T16:18:11+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629"},"wordCount":357,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Geron-Corporation-logo.jpg","keywords":["Geron Corporation (NASDAQ:GERN)","NASDAQ:GERN"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629","url":"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629","name":"Geron Corporation (NASDAQ:GERN) Surging on the FDA Lifting a Partial Hold Ban on Cancer Trial - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Geron-Corporation-logo.jpg","datePublished":"2014-06-12T16:18:11+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Geron-Corporation-logo.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Geron-Corporation-logo.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/geron-corporation-nasdaqgern-surging-on-the-fda-lifting-a-partial-hold-ban-on-cancer-trial-25629#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Geron Corporation (NASDAQ:GERN) Surging on the FDA Lifting a Partial Hold Ban on Cancer Trial"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90","name":"Alan Masterson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","caption":"Alan Masterson"},"description":"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/25629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=25629"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/25629\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/17274"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=25629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=25629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=25629"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=25629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}